Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
3.65
USD
|
+1.39%
|
|
-4.70%
|
-73.95%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
374.3
|
96.96
|
-
|
-
|
Enterprise Value (EV)
1 |
374.3
|
95.77
|
91.9
|
96.96
|
P/E ratio
|
-12.1
x
|
-3.53
x
|
-3.08
x
|
-3.4
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,202
x
|
24,239
x
|
-
|
3.4
x
|
EV / Revenue
|
2,202
x
|
23,944
x
|
-
|
3.4
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-17.6
x
|
-3.99
x
|
-2.42
x
|
-3.59
x
|
FCF Yield
|
-5.69%
|
-25.1%
|
-41.4%
|
-27.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,718
|
26,563
|
-
|
-
|
Reference price
2 |
14.01
|
3.650
|
3.650
|
3.650
|
Announcement Date
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
11.07
|
0.17
|
0.004
|
-
|
28.55
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-3.013
|
-24.16
|
-25.19
|
-35.37
|
-36.43
|
Operating Margin
|
-
|
-27.22%
|
-14,214.71%
|
-629,693.75%
|
-
|
-127.6%
|
Earnings before Tax (EBT)
1 |
-
|
-4.107
|
-28.3
|
-28.49
|
-35.27
|
-35.88
|
Net income
1 |
-16.38
|
-5.207
|
-28.3
|
-28.49
|
-35.27
|
-35.88
|
Net margin
|
-
|
-47.05%
|
-16,645.29%
|
-712,137.5%
|
-
|
-125.68%
|
EPS
2 |
-0.6000
|
-0.2100
|
-1.160
|
-1.035
|
-1.187
|
-1.075
|
Free Cash Flow
1 |
-
|
-
|
-21.3
|
-24
|
-38
|
-27
|
FCF margin
|
-
|
-
|
-12,529.41%
|
-600,000%
|
-
|
-94.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/24/22
|
3/29/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.17
|
-
|
-
|
-
|
0.008
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.462
|
-5.395
|
-5.307
|
-7.001
|
-8.115
|
-5.831
|
-6.024
|
-6.196
|
-6.1
|
-6.1
|
Operating Margin
|
-3,801.18%
|
-
|
-
|
-
|
-101,437.5%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.36
|
-5.821
|
-5.345
|
-6.767
|
-7.85
|
-6.938
|
-7.124
|
-7.367
|
-6.1
|
-6.1
|
Net income
1 |
-10.36
|
-5.821
|
-5.345
|
-6.767
|
-7.85
|
-6.938
|
-7.124
|
-7.367
|
-6.1
|
-6.1
|
Net margin
|
-6,096.47%
|
-
|
-
|
-
|
-98,125%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5300
|
-0.2300
|
-0.2000
|
-0.2500
|
-0.2900
|
-0.2600
|
-0.2500
|
-0.2600
|
-0.2300
|
-0.2300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/15/23
|
8/14/23
|
11/14/23
|
3/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
24.5
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
1.18
|
5.06
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-21.3
|
-24
|
-38
|
-27
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.05
|
1.03
|
0.7
|
1.2
|
3
|
Capex / Sales
|
-
|
0.44%
|
602.94%
|
17,500%
|
-
|
10.51%
|
Announcement Date
|
6/24/22
|
3/29/23
|
3/29/24
|
-
|
-
|
-
|
Last Close Price
3.65
USD Average target price
26
USD Spread / Average Target +612.33% Consensus |
1st Jan change
|
Capi.
|
---|
| -73.95% | 96.96M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|